David G Brauer1, Ryan C Fields1, Benjamin R Tan2, M B Majella Doyle1, Chet W Hammill1, William G Hawkins1, Graham A Colditz1, William C Chapman3. 1. Department of Surgery, Washington University School of Medicine, Alvin J. Siteman Cancer Center, St Louis, MO, USA. 2. Division of Oncology, Department of Medicine, Washington University School of Medicine, Alvin J. Siteman Cancer Center, St Louis, MO, USA. 3. Department of Surgery, Washington University School of Medicine, Alvin J. Siteman Cancer Center, St Louis, MO, USA. Electronic address: chapmanw@wustl.edu.
Abstract
BACKGROUND: Lymph node (LN) status is an important predictor of overall survival for resected IHCC, yet guidelines for the extent of LN dissection are not evidence-based. We evaluated whether the number of LNs resected at the time of surgery is associated with overall survival for IHCC. METHODS: Patients undergoing curative-intent (R0 or R1) resection for IHCC between 2004 and 2012 were identified within the US National Cancer Database. LN thresholds were evaluated using maximal chi-square testing and five-year overall survival was modeled using Kaplan-Meier and Cox regressions. RESULTS: 57% (n = 1,132) of 2,000 patients had one or more LNs resected and pathologically examined. In the 631 patients undergoing R0 resection with pN0 disease, maximal chi-square testing identified ≥3 LNs as the threshold most closely associated with overall survival. Only 39% of resections reached this threshold. On multivariable survival analysis, no threshold of LNs was associated with overall survival, including ≥3 LNs (p = 0.186) and the current American Joint Committee on Cancer recommendation of ≥6 LNs (p = 0.318). CONCLUSION: In determining the extent of lymphadenectomy at the time of curative-intent resection for IHCC, surgeons should carefully consider the prognostic yield in the absence of overall survival benefit.
BACKGROUND: Lymph node (LN) status is an important predictor of overall survival for resected IHCC, yet guidelines for the extent of LN dissection are not evidence-based. We evaluated whether the number of LNs resected at the time of surgery is associated with overall survival for IHCC. METHODS:Patients undergoing curative-intent (R0 or R1) resection for IHCC between 2004 and 2012 were identified within the US National Cancer Database. LN thresholds were evaluated using maximal chi-square testing and five-year overall survival was modeled using Kaplan-Meier and Cox regressions. RESULTS: 57% (n = 1,132) of 2,000 patients had one or more LNs resected and pathologically examined. In the 631 patients undergoing R0 resection with pN0 disease, maximal chi-square testing identified ≥3 LNs as the threshold most closely associated with overall survival. Only 39% of resections reached this threshold. On multivariable survival analysis, no threshold of LNs was associated with overall survival, including ≥3 LNs (p = 0.186) and the current American Joint Committee on Cancer recommendation of ≥6 LNs (p = 0.318). CONCLUSION: In determining the extent of lymphadenectomy at the time of curative-intent resection for IHCC, surgeons should carefully consider the prognostic yield in the absence of overall survival benefit.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Ann Intern Med Date: 2007-10-16 Impact factor: 25.391
Authors: Hiromichi Ito; Kaori Ito; Michael D'Angelica; Mithat Gonen; David Klimstra; Peter Allen; Ronald P DeMatteo; Yuman Fong; Leslie H Blumgart; William R Jarnagin Journal: Ann Surg Date: 2011-08 Impact factor: 12.969
Authors: Kaori Ito; Hiromichi Ito; Peter J Allen; Mithat Gonen; David Klimstra; Michael I D'Angelica; Yuman Fong; Ronald P DeMatteo; Murray F Brennan; Leslie H Blumgart; William R Jarnagin Journal: Ann Surg Date: 2010-04 Impact factor: 12.969
Authors: Itaru Endo; Mithat Gonen; Adam C Yopp; Kimberly M Dalal; Qin Zhou; David Klimstra; Michael D'Angelica; Ronald P DeMatteo; Yuman Fong; Lawrence Schwartz; Nancy Kemeny; Eileen O'Reilly; Ghassan K Abou-Alfa; Hiroshi Shimada; Leslie H Blumgart; William R Jarnagin Journal: Ann Surg Date: 2008-07 Impact factor: 12.969
Authors: Zeljka Jutric; W Cory Johnston; Helena M Hoen; Pippa H Newell; Maria A Cassera; Chet W Hammill; Ronald F Wolf; Paul D Hansen Journal: HPB (Oxford) Date: 2016-01 Impact factor: 3.647
Authors: Patrick J Sweigert; Emanuel Eguia; Haroon Janjua; Sean P Nassoiy; Lawrence M Knab; Gerard Abood; Paul C Kuo; Marshall S Baker Journal: Surg Open Sci Date: 2020-05-16
Authors: Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque Journal: Transl Gastroenterol Hepatol Date: 2018-09-12
Authors: Joshua S Jolissaint; Kevin C Soares; Kenneth P Seier; Ritika Kundra; Mithat Gönen; Paul J Shin; Thomas Boerner; Carlie Sigel; Ramyasree Madupuri; Efsevia Vakiani; Andrea Cercek; James J Harding; Nancy E Kemeny; Louise C Connell; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; T Peter Kingham; Alice C Wei; William R Jarnagin Journal: Clin Cancer Res Date: 2021-05-07 Impact factor: 12.531